Moreover, in patients with non-squamous NSCLC, the functional STK11 mutations result in resistance to PD-1/PD-L1 blockade (anti-PD-L1 antibody durvalumab ± anti-CTLA-4 antibody tremelimumab) immunotherapies, highlighting STK11 as a potential co-biomarker in screening the optimal subpopulation for personalized immune checkpoint therapy (114). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.